Your Top 100 most-cited badge
A badge for your website, a sentence for your CV, and a permanent page where anyone can check the rank.
The article
376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study
Shanu Modi, William Jacot, Hiroji Iwata, Y.H. Park, M.J. Vidal Losada, Wei Li and 14 more
- Rank
- 90 of 3,639
- Percentile
- top 2.5%
- Where
- Annals of Oncology, 2023
- Citations
- 36
From the 2023 list, OpenAlex counts as of 2026-10-29.
Prefer not to be listed? The same link lets you withhold your name on every list; the article stays, your name does not. Questions: team@avidnote.com.